tiprankstipranks
Trending News
More News >
Lepu Biopharma Co. Ltd. Class H (HK:2157)
:2157
Hong Kong Market

Lepu Biopharma Co. Ltd. Class H (2157) Price & Analysis

Compare
3 Followers

2157 Stock Chart & Stats

HK$5.34
-HK$0.04(-1.65%)
At close: 4:00 PM EST
HK$5.34
-HK$0.04(-1.65%)

Lepu Biopharma Co. Ltd. Class H News

2157 FAQ

What was Lepu Biopharma Co. Ltd. Class H’s price range in the past 12 months?
Lepu Biopharma Co. Ltd. Class H lowest stock price was HK$2.26 and its highest was HK$10.50 in the past 12 months.
    What is Lepu Biopharma Co. Ltd. Class H’s market cap?
    Lepu Biopharma Co. Ltd. Class H’s market cap is HK$9.93B.
      When is Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date?
      Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date is Apr 01, 2026 which is in 105 days.
        How were Lepu Biopharma Co. Ltd. Class H’s earnings last quarter?
        Lepu Biopharma Co. Ltd. Class H released its earnings results on Aug 20, 2025. The company reported HK$0.022 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.022.
          Is Lepu Biopharma Co. Ltd. Class H overvalued?
          According to Wall Street analysts Lepu Biopharma Co. Ltd. Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Lepu Biopharma Co. Ltd. Class H pay dividends?
            Lepu Biopharma Co. Ltd. Class H does not currently pay dividends.
            What is Lepu Biopharma Co. Ltd. Class H’s EPS estimate?
            Lepu Biopharma Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Lepu Biopharma Co. Ltd. Class H have?
            Lepu Biopharma Co. Ltd. Class H has 1,804,439,800 shares outstanding.
              What happened to Lepu Biopharma Co. Ltd. Class H’s price movement after its last earnings report?
              Lepu Biopharma Co. Ltd. Class H reported an EPS of HK$0.022 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -6.035%.
                Which hedge fund is a major shareholder of Lepu Biopharma Co. Ltd. Class H?
                Currently, no hedge funds are holding shares in HK:2157
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Lepu Biopharma Co. Ltd. Class H Stock Smart Score

                  5
                  Neutral
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Company Description

                  Lepu Biopharma Co. Ltd. Class H

                  Lepu Biopharma Co. Ltd. Class H (2157) is a biopharmaceutical company based in China, specializing in the research, development, manufacturing, and commercialization of innovative therapies and diagnostics. The company operates primarily in the fields of oncology, cardiovascular diseases, and autoimmune disorders, providing a range of products including monoclonal antibodies, biosimilars, and diagnostic kits. Lepu Biopharma is committed to improving healthcare outcomes through advanced biopharmaceutical solutions and is focused on expanding its presence both domestically and internationally.

                  Lepu Biopharma Co. Ltd. Class H (2157) Earnings & Revenues

                  2157 Stock 12 Month Forecast

                  Average Price Target

                  HK$9.96
                  ▲(86.52% Upside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"HK$1","10":"HK$10","3.25":"HK$3.25","5.5":"HK$5.5","7.75":"HK$7.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":9.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$9.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$9.96</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9.96,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$9.96</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.25,5.5,7.75,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Apr<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.94,8.095384615384615,8.250769230769231,8.406153846153847,8.561538461538461,8.716923076923077,8.872307692307693,9.027692307692309,9.183076923076923,9.338461538461539,9.493846153846155,9.64923076923077,9.804615384615385,{"y":9.96,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.94,8.095384615384615,8.250769230769231,8.406153846153847,8.561538461538461,8.716923076923077,8.872307692307693,9.027692307692309,9.183076923076923,9.338461538461539,9.493846153846155,9.64923076923077,9.804615384615385,{"y":9.96,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.94,8.095384615384615,8.250769230769231,8.406153846153847,8.561538461538461,8.716923076923077,8.872307692307693,9.027692307692309,9.183076923076923,9.338461538461539,9.493846153846155,9.64923076923077,9.804615384615385,{"y":9.96,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.92,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.53,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.96,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.07,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.88,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.62,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.89,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.65,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.23,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.23,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.51,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.4,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Ascletis Pharma, Inc.
                  Keymed Biosciences, Inc.
                  CARsgen Therapeutics Holdings Ltd.
                  Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
                  ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks